iX Biopharma Ltd. (SGX:42C)
Singapore flag Singapore · Delayed Price · Currency is SGD
0.1920
-0.0080 (-4.00%)
Feb 9, 2026, 5:07 PM SGT

iX Biopharma Cash Flow Statement

Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Income
-5.95-10.14-10.79-9.62-4.6-8.23
Depreciation & Amortization
0.780.850.860.891.011
Other Amortization
000.010.040.050.05
Loss (Gain) From Sale of Assets
------0
Loss (Gain) From Sale of Investments
-0.012.51-1.743.26-
Stock-Based Compensation
00.03-0.850.861.381
Provision & Write-off of Bad Debts
0.03-0.11---
Other Operating Activities
0.34.571.462.362.72-1.84
Change in Accounts Receivable
0.430.08-0.11-0.85-0.230.02
Change in Inventory
0.050.31-0.62-0.2-0.04-0.35
Change in Accounts Payable
0.570.480.860.71-0.27-0.07
Change in Other Net Operating Assets
0.040.060-0.12-0.160.07
Operating Cash Flow
-3.73-3.76-6.55-7.663.12-8.35
Capital Expenditures
-0.08-0.2-0.27-0.7-0.2-0.55
Sale of Property, Plant & Equipment
--1.34--0.05
Sale (Purchase) of Intangibles
---0.01---
Investment in Securities
-----5.42-
Investing Cash Flow
-0.08-0.21.06-0.7-5.62-0.51
Long-Term Debt Issued
-1.512.03-1.4-
Long-Term Debt Repaid
--1.05-1.02-0.99-1.02-0.6
Net Debt Issued (Repaid)
1.20.461.01-0.990.37-0.6
Issuance of Common Stock
7.033.25-2.739.6210.18
Other Financing Activities
-0.72-0.59-0.29-0.31-0.20.45
Financing Cash Flow
7.513.120.721.429.7910.02
Foreign Exchange Rate Adjustments
-0.010.01--0.050.03-0.05
Net Cash Flow
3.69-0.83-4.77-6.987.321.12
Free Cash Flow
-3.81-3.96-6.83-8.362.92-8.91
Free Cash Flow Margin
-52.73%-50.97%-114.57%-141.30%20.31%-510.32%
Free Cash Flow Per Share
-0.00-0.01-0.01-0.010.00-0.01
Cash Interest Paid
0.780.680.320.270.20.17
Cash Income Tax Paid
--0.73-0.48-0.54-0.71-0.72
Levered Free Cash Flow
-1.86-1.86-5-6.583.76-6.46
Unlevered Free Cash Flow
-1.49-1.66-4.72-6.413.89-6.36
Change in Working Capital
1.090.930.14-0.45-0.7-0.33
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.